Julian Baker | $1B+

Billionaire

Dec 5

Get in touch with Julian Baker | Julian Baker, cofounder of Baker Bros. Advisors, is one of the most successful investors in the biotechnology industry, building a multibillion-dollar hedge fund focused on high-conviction positions in drug development and life sciences. Together with his brother Felix, he has backed breakthrough therapeutics and major biotech companies including Seagen, Incyte, and Alexion, often taking large, long-term positions and working closely with management teams. Known for rigorous scientific analysis, patience, and a deep understanding of clinical risk, Baker has become a central figure in biotech capital markets, influencing the trajectory of drug innovation while maintaining one of the top track records in the sector.

Baker Brothers Advisors (BBA) is an American hedge fund management firm headquartered in New York. Despite its secretive nature, the firm is a leading biotechnology investor and manages over $20 billion in assets under management (AUM).

Background

BBA was founded in 2000 by brothers Felix and Julian Baker. Their father is Keith Michael Baker, a history professor at Stanford University. Felix graduated from Stanford University with a B.S. in Biology, got a PhD in immunology and completed two years of medical school while Julian graduated from Harvard University with a B.A. in Social studies and then worked in the private equity arm of Credit Suisse First Boston. In 1994, the brothers started managing health care investments for the Laurence Tisch's family who owned the Loews Corporation before creating their own standalone business.[2][3][4][5]

The brothers maintained close ties to the Tisch family and until 2017, the BBA office was in the 667 Madison Avenue skyscraper which was the same one as the Loews Corporation.[2]

Since its inception, BBA has been noted for its secrecy. It has no website and the brothers avoid the press as well as refusal to respond to phone calls for comments on their strategy.[2][5]

Investment strategy

BBA focuses on the biotechnology sector and been noted for its strong returns. Yale University’s charitable foundation had $274 million invested with BBA in 2009 and by 2016 it rose to $1.08 billion, a combination of new money and profits of $393 million. In October 2019, BBA's investment value in two weeks increased by $1.4 billion due to Seagen and BeiGene.[2][3][5] In August 2024, The Wall Street Journal reported that BBA's 25% stake investment in Seagen in 2003 resulted in a windfall gain of $8 billion when in 2023, Pfizer acquired Seagen for $43 billion which was considered one of the largest return on capital investments in the industry. Most of those gains were returned back to investors because it didn't see enough opportunities to deploy all that money at once.[4]

BBA's success has been built on advances in the science of genetics, rise in biotechnology stocks and a period of dealmaking as large biopharmaceutical companies acquire up smaller innovators. BBA relies on talented executives and scientists which are often discovered at companies it invests in and frequently end up on the board of directors in other companies in BBA's portfolio. As of 2019, BBA's top 20 disclosed public company investments eight have at least one board member who are BBA employees. Chief executives for 7 of those 20 companies also serve as board members for other companies that are BBA investments. Some welcome BBA's influence such as Eve Slater who has stated the representatives are "very scientifically driven" and "active". Others are more critical of BBA's influence such as RA Capital Management who felt BBA's influence in a now-rejected deal to merge BioCryst Pharmaceuticals with Idera Pharmaceuticals significantly favoured BBA at the expense of other shareholders.[

Disclaimer: This profile is based on publicly available information. No endorsement or affiliation is implied.

Join UHNWI direct Affiliate Program

Earn Passive Income by Sharing Verified Contact Information of Billionaires, Centi-Millionaires, and Multi-Millionaires on the UHNWI Direct Platform

Maximize your earnings potential by sharing direct and validated contact information of the ultra-wealthy, including billionaires, centi-millionaires, and multi-millionaires. Join the UHNWI Direct platform and tap into a lucrative passive income stream by providing valuable data to those seeking high-net-worth connections. Start earning today with UHNWI Direct.

Apply to Join Affiliate Program

You may also be interested in reviewing other UHNWIs profiles.

To find the person you want to contact, start typing their name or other relevant tags in the search bar.

Please note: Our database contains over 10,000 direct contacts of UHNWIs, and it is highly likely that the individual you are seeking is already included. However, creating individual profiles for each contact is a meticulous and time-intensive process, So, if you are unable to find the profile of the individual you are looking for, please click here.

Filter by Net Worth: All | Billionaires | Centi-Millionaires | Multi-Millionaires

Filter by Age: 1920-1930 | 1930-1940 | 1940-1950 | 1950-1960 | 1960-1970 | 1970-1980 | 1980-1990 | 1990-2000

Filter by: Men | Women

Related People

UHNWI direct

Karthik Sarma | $1B+

Karthik Sarma, founder of SRS Investment Management, is the hedge fund manager who turned a concentrated activist position in Avis Budget Group into one of the most spectacular investment wins of the past decade. After founding SRS in 2006, the former Tiger Cub built a reputation for deep, research-driven conviction, long time horizons, and strategic influence behind the scenes. His most famous trade—SRS’s stake in Avis—generated multibillion-dollar gains as the company’s market value surged, making Sarma one of the top-earning hedge fund managers in America. Known for his low profile, analytical intensity, and disciplined patience, he has become a defining figure in modern activist investing.

Julian Baker | $1B+

Julian Baker, cofounder of Baker Bros. Advisors, is one of the most successful investors in the biotechnology industry, building a multibillion-dollar hedge fund focused on high-conviction positions in drug development and life sciences. Together with his brother Felix, he has backed breakthrough therapeutics and major biotech companies including Seagen, Incyte, and Alexion, often taking large, long-term positions and working closely with management teams. Known for rigorous scientific analysis, patience, and a deep understanding of clinical risk, Baker has become a central figure in biotech capital markets, influencing the trajectory of drug innovation while maintaining one of the top track records in the sector.

Joseph Edelman | $1B+

Joseph Edelman, founder and CEO of Perceptive Advisors, is one of the most successful and influential biotech hedge fund managers of the modern era. Since launching the firm in 1999, he has built Perceptive into a multibillion-dollar powerhouse specializing in life sciences, backing breakthrough companies across biotechnology, medical devices, and healthcare innovation. Known for his deep scientific understanding, high-conviction portfolio strategy, and early identification of transformative therapies, Edelman has consistently ranked among the top performers in healthcare investing. His disciplined, research-driven approach has made Perceptive a critical source of capital for emerging biotech and a defining force in the global life sciences ecosystem.

John Paulson | $1B+

John Paulson, founder of Paulson & Co., is one of the most storied figures in modern hedge fund history, best known for his legendary 2007 bet against subprime mortgages that generated profits of more than $15 billion and made him a symbol of prescient, contrarian investing. After building his firm on merger arbitrage and event-driven strategies, Paulson’s success in the financial crisis cemented his reputation as a master of timing and risk management. In recent years, he has shifted toward private investments and family-office operations while becoming a major philanthropist across healthcare, education, and the arts. Paulson’s rise from modest beginnings to one of the wealthiest hedge fund investors underscores the enduring power of disciplined conviction in global markets.

John Overdeck | $1B+

John Overdeck, cofounder and co-chairman of Two Sigma, is one of the key architects of quantitative hedge fund investing, bringing machine learning, distributed computing, and massive data science into the heart of portfolio management. After an award-winning math background and early leadership roles at D.E. Shaw and Amazon, he partnered with David Siegel in 2001 to build Two Sigma into a global multi-strategy platform managing tens of billions across equities, private investments, insurance tech, venture capital, and market-making. A champion of mathematics and education, Overdeck is also a leading philanthropist through the Overdeck Family Foundation, advancing STEM learning and research at scale.

John Liew | $1B+

John Liew, cofounder of AQR Capital Management, is one of the intellectual architects behind quantitative investing, helping bring academic finance into large-scale asset management. Working alongside Cliff Asness and David Kabiller, Liew transformed ideas rooted in factor research, risk premia, and systematic portfolio construction into a multi-hundred-billion-dollar investment platform serving institutions worldwide. With a PhD from the University of Chicago under Nobel laureates, he has championed evidence-based strategies in equities, alternatives, and global macro, while remaining a leading voice in the dialogue between academia and asset management. Liew’s work has been pivotal in cementing quant finance as a mainstream discipline.

John Griffin | $1B+

John Griffin, founder of Blue Ridge Capital, became one of the most respected hedge fund managers of his generation through his disciplined long/short equity strategy and reputation for deep fundamental research. A protégé of legendary investor Julian Robertson at Tiger Management, Griffin launched Blue Ridge in 1996 and built it into a multi-billion-dollar “Tiger Cub” fund known for concentrated bets on high-quality growth companies and sharp downside hedging. After closing the fund in 2017 to devote himself to philanthropy, he became CEO of Blue Ridge Foundation and a leading donor to education and medical research, combining investment principles with data-driven social impact initiatives.

John Arnold | $1B+

John Arnold, former hedge fund trader and cofounder of Arnold Ventures, built one of the most successful careers in energy trading before devoting his wealth to large-scale philanthropy. After rising quickly at Enron’s trading desk, he launched Centaurus Energy in 2002 and became known for prescient bets on natural gas markets that produced billions in profits, earning a reputation as one of the most skilled traders of his generation. Retiring from finance in his 30s, Arnold shifted his focus to philanthropic work through Arnold Ventures, targeting data-driven policy reform in criminal justice, healthcare, education, and public finance. His rare trajectory from billionaire trader to systems-change philanthropist has made him a uniquely influential figure in both markets and public policy.

Jeffrey Talpins | $1B+

Jeffrey Talpins, founder, CEO and Chief Investment Officer of Element Capital Management, is a leading architect of the “modern macro” hedge fund era. Launching Element in 2005 after distinguished fixed-income roles at Goldman Sachs and Citigroup, Talpins built the firm into a multi-billion-dollar platform famed for its disciplined, systematic global-macro strategies and strong historical performance. Under his leadership, Element returned 21 % annualized since inception and at one point managed over $18 billion in assets. Talpins also channels his success into high-impact philanthropy, including conservation, education, and peace initiatives through the Jeffrey M. Talpins Foundation.

Jamie Dinan | $1B+

Jamie Dinan, founder and CEO of York Capital Management, is one of the most respected figures in the hedge fund world, known for his disciplined event-driven and distressed investing strategies. After losing his entire savings during the 1987 market crash, Dinan rebuilt his career and launched York in 1991 with just $3.6 million, growing it into a multibillion-dollar global firm with offices in New York, London, and Hong Kong. Renowned for his resilience, rigorous analysis, and long-term perspective, Dinan also holds ownership stakes in major sports franchises and is an active philanthropist in education and healthcare.

Israel Englander | $10B+

Israel Englander, billionaire hedge fund manager, is the founder and CEO of Millennium Management, one of the world’s largest and most successful multi-strategy hedge funds. Launching the firm in 1989 with $35 million, he has grown Millennium into a powerhouse managing more than $50 billion in assets, employing a decentralized model with hundreds of portfolio managers. Known for his risk management discipline and ability to adapt to shifting markets, Englander has built a reputation as one of the most influential figures in modern hedge fund investing.

Greg Jensen | $1B+

Greg Jensen, co–chief investment officer of Bridgewater Associates, helps oversee the world’s largest hedge fund with more than $150 billion under management. Joining the firm in 1996, he rose through the ranks under founder Ray Dalio to become one of Bridgewater’s top strategists, shaping its macroeconomic research and investment frameworks. Known for his analytical rigor and role in refining the firm’s “Principles”-driven culture, Jensen has been instrumental in maintaining Bridgewater’s dominance in global macro investing and guiding its long-term strategic direction.

Glenn Dubin | $1B+

Glenn Dubin, billionaire hedge fund manager and philanthropist, cofounded Highbridge Capital Management in 1992, growing it into one of the world’s premier alternative investment firms before selling a majority stake to JPMorgan Chase in 2004. After leaving Highbridge, he launched Dubin & Co., a private investment firm with interests spanning energy, healthcare, and consumer businesses. Known for his disciplined approach to investing and extensive philanthropic commitments in health, education, and community development, Dubin has cemented his reputation as both a savvy financier and committed benefactor.

Francis Biondi | $1B+

O. Francis Biondi, cofounder of King Street Capital Management, launched the hedge fund in 1995 alongside fellow First Boston alum Brian Higgins, building it into a global powerhouse with over $25 billion in assets under management. Specializing in contrarian plays across stocks and bonds, the firm became a dominant force in distressed and value investing. Biondi retired in 2020 but retained his ownership stake, cementing his legacy as a shrewd investor and architect of one of the most respected names in alternative asset management.

Felix Baker | $1B+

Felix Baker is a highly influential biotech-focused investor and co-founder of Baker Brothers Advisors, a leading hedge fund specializing in healthcare and biotechnology investing. Through his firm, established in 2000, Felix manages over $20 billion in assets and helped generate an estimated $8 billion gain from early investments in Seagen. A PhD immunologist and Stanford alumnus, he also serves on boards of key biotech companies and contributes to Stanford’s biosciences initiatives.

Edward Lampert | $1B+

Edward Scott “Eddie” Lampert is an American billionaire investor and founder of ESL Investments, established in 1988 after stints at Goldman Sachs and backing from Richard Rainwater. He famously orchestrated the merger of Kmart and Sears in 2005 and led Sears Holdings until 2019, after acquiring it via bankruptcy auction through Transformco. His record has been polarizing—praised for contrarian success at AutoZone and AutoNation, yet widely criticized for Sears’ collapse.

Dirk Ziff | $1B+

Dirk Edward Ziff is an American billionaire investor and media heir—the eldest son of William B. Ziff Jr., who sold the Ziff‑Davis publishing empire for $1.4 billion in 1994. Along with his brothers, Dirk formed Ziff Brothers Investments, spanning hedge funds, private equity, real estate, commodities, and seed‑stage finance. He later seeded Daniel Och’s Och‑Ziff Capital Management before dissolving the partnership in 2014 to invest independently.

David Siegel | $1B+

David M. Siegel is an American computer scientist turned investor who co-founded Two Sigma Investments in 2001 alongside John Overdeck. With a PhD in Computer Science from MIT and early roles at D. E. Shaw and Tudor, Siegel helped build Two Sigma into a quant trading powerhouse managing roughly $60 billion in assets. He now serves as co-chairman and leads the firm’s technology and philanthropy initiatives through the Siegel Family Endowment.

David Shaw | $1B+

David E. Shaw is the Stanford‑trained computer scientist turned Wall Street quant and billionaire founder of D. E. Shaw & Co.. Launched in 1988 with $28 million, the firm pioneered algorithmic trading and grew into one of the world’s largest hedge funds—managing ~$65 billion in assets by 2025. Shaw stepped back from daily operations in 2001 to lead D. E. Shaw Research, advancing computational biochemistry and molecular-dynamics simulations.

David Kabiller | $1B+

David Kabiller is the co‑founding principal and Head of Business Development at AQR Capital Management, the global quantitative investment firm he launched in 1998 alongside Cliff Asness and others. He spearheaded AQR’s international expansion, retail mutual fund offerings, and educational initiatives such as AQR University and the AQR Insight Award. A former athlete, he holds degrees in economics and finance from Northwestern and continues to support research via prizes at Northwestern and London Business School.

David Einhorn | $1B+

David Einhorn is the founder and president of Greenlight Capital, a value-oriented long/short hedge fund founded in 1996. Known for accurately shorting Lehman Brothers and Allied Capital, he built Greenlight into a firm delivering annualized returns around 15–26% in its early years. In early 2025, the fund gained ~12%—with gold leading portfolio performance—even amid a bearish pivot during volatile markets.

Daniel Sundheim | $1B+

Daniel Sundheim is the American billionaire founder and Chief Investment Officer of D1 Capital Partners, a high-conviction global investment firm launched in 2018. A former CIO at Viking Global with 15 years of experience, he built D1 into a multi‑billion‑dollar firm investing across public and private markets—including leading positions in Instacart and SpaceX. He also serves on boards of MoMA, NYU Langone, and Columbia Grammar.

Daniel Och | $1B+

Daniel Och is the American billionaire founder of Och‑Ziff Capital Management (rebranded as Sculptor Capital in 2019). A Wharton alumnus and former Goldman Sachs equities trader, he built Och‑Ziff into a major hedge fund managing tens of billions before stepping down in 2019. He now runs Willoughby Capital, a family office investing in tech startups like Robinhood, Coinbase, and Instacart, while leading major philanthropic initiatives.

Daniel Loeb | $1B+

Daniel Loeb is an American investor, hedge‑fund manager, and founder & CEO of Third Point LLC, a New York‑based activist investment firm launched in 1995 with ~$3–4 million in capital. Renowned for his scathing public letters and event‑driven strategy, he has built Third Point into a multi‑billion‑dollar fund and a major force in corporate turnarounds and governance reform. He is also a philanthropist active in education and civil‑rights causes.

Clifford Asness | $1B+

Clifford “Cliff” Asness is the co‑founder, Managing Principal & Chief Investment Officer of AQR Capital Management, a quantitative investment firm managing roughly $120 billion in assets. A PhD from the University of Chicago and former Goldman Sachs quant strategist, he popularized factor-based investing and author of influential research on value, momentum, and market efficiency.

Chase Coleman, III | $1B+

Chase Coleman III is the founder and managing partner of Tiger Global Management, one of the most powerful hedge funds and venture firms globally. A protégé of Julian Robertson, Coleman runs public and private tech-heavy investment strategies, overseeing around $46 billion in assets while building Tiger Global into a benchmark of high-growth returns. He is also active in education and conservation philanthropy.

Bruce Kovner | $1B+

Bruce Kovner is a self-made hedge fund billionaire and the founder of Caxton Associates in 1983, the global macro fund he led for nearly three decades. A Harvard graduate who once drove a NYC taxi and dabbled in harpsichord before launching a career in trading, Kovner turned $3,000 borrowed on a credit card into billions—later retiring to manage his firm CAM Capital and lead elite arts and education philanthropy.

Brian Higgins | $1B+

Brian Higgins is the co‑founder, managing partner, and co-portfolio manager of King Street Capital Management, a leading global alternative investment firm founded in 1995. Known for excellence in distressed‑debt and credit strategies, Higgins has helped steer the firm through market cycles with disciplined execution and low public profile. He also serves on the board of Harlem Children’s Zone and is recognized for long‑term philanthropic commitments.

Steve Cohen | $10B+

Steve Cohen is an American billionaire hedge fund manager, art collector, and owner of the New York Mets. He is the founder of Point72 Asset Management and S.A.C. Capital Advisors, renowned for his aggressive trading strategies and substantial influence in both the financial and sports industries.

David Tepper | $10B+

David Tepper is an American billionaire hedge fund manager, philanthropist, and owner of the Carolina Panthers of the NFL and Charlotte FC of Major League Soccer. Known for his astute investment strategies and significant charitable contributions, Tepper has made a substantial impact in the financial world and beyond.

UHNWI data is an independent wealth intelligence initiative led by a team of data researchers dedicated to building the world’s most comprehensive archive of individuals with a net worth exceeding $100 million. We believe in open access to structured knowledge — freely available, meticulously curated, and ethically maintained. This work is complex, time-intensive, and demands significant resources. If you find value in what we do, we invite you to support our mission with a donation. Your contribution helps preserve the independence, depth, and lasting impact of this unique research project.

$5.00

$10.00

$20.00

$30.00

$50.00

$100.00

Custom Amount

Support us by covering the fees we have to pay

3% Cover the Fee

Marketing Tools

Essential marketing tools to effectively engage wealthy individuals, tailored to meet any personal, marketing, or sales objectives.

Use tags below for more precise targeting.

ManBillionaireUSAJulian Baker1960-1970Felix BakerInvestment managementHedge FundBiotechnologyInvesting in biotechnologyBiotech investingNew YorkAndrew TischJames TischJonathan Tisch

UHNWI data https://www.uhnwidata.com/

Julian Baker | $1B+

Join UHNWI direct Affiliate Program

Earn Passive Income by Sharing Verified Contact Information of Billionaires, Centi-Millionaires, and Multi-Millionaires on the UHNWI Direct Platform

You may also be interested in reviewing other UHNWIs profiles.

Related People

Support our Research

Marketing Tools

Essential marketing tools to effectively engage wealthy individuals, tailored to meet any personal, marketing, or sales objectives.

Use tags below for more precise targeting.

Julio Santo Domingo | $1B+

Jude Reyes | $10B+